The whole genome sequences of Jim Watson and Craig Venter are early examples of personalized genomics, which promises to change how we approach healthcare in the future. Before personal sequencing can have practical medical benefits, however, and before it should be advocated for implementation at the population-scale, there needs to be a better understanding of which genetic variants influence which traits and how their effects are modified by epigenetic factors. Nonetheless, for forging links between DNA sequence and phenotype, efforts to sequence the genomes of individuals need to continue; this includes sequencing sub-populations for association studies which analyse the difference in sequence between disease affected and unaffected individuals. Such studies can only be applied on a large enough scale to be effective if the massive strides in sequencing technology that have recently occurred also continue.
INTRODUCTION
The sequencing of Jim Watson [1] , Craig Venter [2] and now others [3] [4] [5] [6] [7] [8] [9] [10] has provided substantially complete surveys of individual human genomes. In comparison to the mosaic of genomes represented in the human reference sequence [11, 12] , the diploid sequencing of individuals of known identity enables genotype-phenotype correlations to be studied for the first time in the context of the whole human genome.
Much has been made about how such personal genome sequencing could be applied to populations for preventative and tailored health management and treatment [13] . The complete genome sequencing of normal (skin) and abnormal (bone marrow) genomes in two patients, a female [6] and a male [7] , diagnosed with acute myeloid leukaemia (AML) illustrates the potential utility of personal sequencing. The intra-individual genome comparisons reveal somatic mutations which may have contributed to the cancer. This approach could lead to treatments that are tailored to the cancer sub-type defined by the variants present in an individual [14] . Before personal sequencing can be contemplated on a population-scale a key question that remains, however, is whether the likelihood of developing disease can be predicted by sequencing of healthy individuals well before symptoms become manifest?
Genetic variation comprises single nucleotide variants (SNVs) and all length-scales of structural variants (SVs) comprising insertions, deletions, inversions, copy number variants (CNVs) and balanced translocations. There are >10 million common single nucleotide polymorphisms [SNPs: SNVs that are common with >1% minor allele frequency (MAF)] in the human genome [15] ; the HapMap project [16] enabled the SNP diversity to be subdivided according to haplotype blocks-alleles associated on a single parental chromosome-'tagged' by a sub-set of informative SNPs. The fact that more base pairs in the genome are devoted to common CNV than SNPs, has only recently come to light (74% of Craig Venter's variant bases) [2] .
Currently, our ability to translate genetic variants into risk factors for common disease remains rudimentary. Type 2 diabetes (T2D), rheumatoid arthritis, bipolar disorder amongst many other chronic diseases which are prevalent in society are complex, combining environmental factors with contributions from a plurality of genetic components. Until very recently, there had been little progress in finding the genetic risk factors that underlie such traits. This began to change in 2007, when the use of high density SNP chips carrying tagSNPs in conjunction with large numbers of case and control subjects enabled the Wellcome Trust Case Control Consortium (WTCC; http://www.wtccc.org.uk/) to carry out genome wide association studies (GWAS) that were for the first time sufficiently statistically powered to detect genetic risk factors of moderate effect [17] . A large number of further studies have since been carried out and loci associated with genetic risk have been identified for an increasing list of conditions (http://www.genome.gov/ gwastudies/#1) [18] (see also Panoutsopoulou and Zeggini in this issue [19] ).
GWASs are based on the Common DiseaseCommon Variant hypothesis (CD-CV) [20] , which posits that because the disease is common in populations, the variants responsible must be shared and hence common too; it now seems clear that this can only be part of the story. While GWAS studies have shown that common variants are indeed associated with several of the common diseases, they typically appear to account for only 10% or so of the heritable risk associated with each of those diseases [17] . Has the heritability component of common diseases been overestimated? The contribution of intrauterine epigenetic effects in monozygotic twins might have been overlooked [21] . This, however, is unlikely to adjust heritability estimates to a significant extent nor negate the view that there is a substantial genetic effect [22] . So where lays the remaining 90% of heritability?
The counterpoint to CD-CV is the Common Disease-Rare Variant (CD-RV) hypothesis, which argues that common disease comprises variants that are rare in the population [23] [24] [25] [26] . Rare SNVs are those that have <1% MAF; the subset with <0.1% MAF are likely to have arisen de novo in the population and may be private to a family or an individual [15] . A number of studies have compared cases and controls by sequencing one or more candidate genes and found that rare variants were enriched in the cases (summarized in ref. [24] ). Also the nature of rare variants that have been found in coding regions suggest that a relatively large number may have phenotypic consequence [27] . As rare variants will have occurred recently in evolutionary history they do not tend to segregate with the common SNPs that have initially featured on SNP chips. In order to provide an improved resource for SNP tagging and fine-scale mapping short-read sequencing technology is being used in the 1000 Genomes project (http://www .1000genomes.org) to catalogue variants at frequencies lower than accessed ever before (!0.1% MAF in coding regions and !1% outside coding regions).
Although previously noted as likely to play a role in human phenotype [28] the extent of common CNV has only recently become fully appreciated [29] [30] [31] . However, as common CNV is already tagged by the GWAS studies being conducted today [32] , it is unlikely to account for much of the missing heritability. Therefore, it is the recently occurring rare structural variants, which are not captured by GWAS but which are already known to impact a number of conditions [33, 34] that merit further investigation. At present, some forms of rare CNV can be investigated alongside GWAS by array CGH; however, this method cannot access balanced translocations or inversions and does not have the resolution to pinpoint chromosome breakpoints.
While GWAS mapped SNPs may offer a degree of disease predictive value, until the variant responsible for GWAS signal within the tagged region(s) is located, we will have little indication of the biological process that is affected. For this, finemapping, which can be done by variant discovery followed by typing in a large number of individuals, is needed. Arguably, the best way to pinpoint the functional DNA variants within loci mapped by linkage or association studies is DNA sequencing which will detect and identify the variant. Sequencing of individuals will also detect rare SNVs and depending on implementation could access SV (see below). Since the 1980s, the Sanger method [35] had been the sequencing method of choice, its incremental improvement and industrialization resulting in the completion of the Human Genome Project [11, 12] . However, Sanger sequencing was used for only one of the recently sequenced individual genomes [2] . For large-scale sequencing, a second or 'next' generation of sequencing technologies, which comprise massively parallel cycles of surfacebased sequencing-by-synthesis [36] have largely taken over from the Sanger procedure.
In light of the emergence of individual genome sequencing, in this review we consider how DNA sequencing will influence genetic studies to find the variants that underlie common diseases, noting that sequencing will lead to detection of both common and rare variants. We will look at the nature of sequencing technologies in use today and comment on future developments that are needed, particularly those that may encompass structural variants and haplotypes.
NEXT GENERATION SEQUENCING
The next generation sequencing methods which comprise 454 [37] , Polony [38] , SOLID [8] , Solexa [4] and Helicos [39] sequencing, compared with Sanger sequencing are faster, lower-cost, are able to tackle non-clonable regions of the genome responsible for gaps in Sanger genome assemblies. Moreover, they require much less space and infrastructure than Sanger sequencing for generating the raw sequence data. However, read lengths in currently available systems are shorter than the Sanger method and this necessitates substantial informatics infrastructure downstream of generating the raw data. Furthermore, systematic biases such as ambiguity in the number of bases in a homopolymer run and gaps in AT rich areas [40] or a gradually increasing error rate beyond a 12 base read [41, 42] are introduced by one or other of the new technologies. Currently accepted 'finished' genome sequencing accuracy of 99.99% (http://www.genome.gov/ 10000923) still allows for 600 000 errors in the human genome [43] ; this could compromise efforts to determine rare variants. Also, if sequence information is to be used for health management it is paramount that error is reduced perhaps to one in a million [44] . Although an approach for detecting rare allelic variants at frequencies below the consensus error rate of the Solexa sequencing platform has recently been investigated [41] , efforts to reduce error rates should continue [45] .
The whole-genome shotgun sequencing [46, 47] of current technology is subject to Poisson statistics which means that sequencing needs to be done to a substantial depth to ensure all parts of the genome are adequately represented; for Sanger read lengths >99.9% coverage requires 8-10Â read depth [48] . Although haploid sequencing (where only one of the alleles is called) as done in the human genome mapping project (HGMP) [11] , may be useful from the perspective of looking at general features of the genome, it is the diploid sequence (where both alleles are called) which is needed for detecting heterozygosity and making genotype-phenotype correlations. Although using longer Sanger reads diploid coverage was obtained over parts of Venter's genome using 7.5Â coverage, 25Â or more coverage is needed with short-reads [45, 49] . The reason for the increase is so that DNA from both parental chromosomes is covered with reads and to produce a consensus sequence which is essential to weed out low-accuracy reads [2, 10] . Also, the greater the number of reads over a region of the genome, the easier it is to detect rare variants and to sequence highly variable parts of the genome such as the immunoglobulin VDJ regions [50] . A high read depth (or deep sequencing) is also needed when samples are pooled in association studies. The read depth (RD) coverage can also report on copy number variation [9, 51] ; Deletions (one or no copy) are characterized by lower than expected read depth and increasing copy number by higher than expected read depths.
For many clinical applications the sequencing should be deep enough to detect variants, which in the case of cancer biopsies may be rare, due to contamination from stromal and bacterial genomes. For diagnostic next generation sequencing [52, 53] deep sequencing (e.g. 50X) needs to be combined with multiplexing (see below) to make the analysis costeffective and to take advantage of the high number of reads provided by a next generation sequencing run. Deep sequencing is also needed when the goal is to use sequencing simply as a means to count the frequency of particular sequences. For example, for pre-natal testing, foetal chromosome aneuploidy can be detected by evaluating the number of reads obtained from specific chromosomes [54, 55] .
GENOMIC SELECTION AND MULTIPLEXING
A logical extension of a GWAS is to zoom in and sequence the region(s) mapped by the study to look for functional variants. While regions mapped by traditional family-based linkage studies were typically too large to fully sequence, the chromosomal intervals to which loci are mapped using GWAS are somewhat more manageable, usually between 10 and 250 kb [18, 56] . Where genomic annotation [57] reveals specific genes, within these regions, they can often be handled by various PCR regimens including long-range PCR; alternative methods of selective sequencing are also under development (see below). One strategy would be to sequence mapped loci in cases and controls to look directly for rare variants; however this will probably not be feasible on a wide-scale until the cost of sequencing reduces further. Another strategy and one that has recently been exemplified [58] is to pool sample DNA separately for patients and controls and to resequence at a depth that enables low frequency variants to be detected by comparing allele frequencies between case and control pools. Nejentsev et al. sequenced exons and splice sites in one of four possible genes within a locus mapped by GWAS as well as nine candidate genes for type 1 diabetes (T1D); they were able to show association with rare protective alleles in the GWAS mapped locus. Although rare variants which are likely to have arisen recently in evolutionary history are not captured by tagSNPs, Nejentsev et al's work demonstrates that sequencing GWAS regions can coincidentally reveal the presence of rare variants at GWAS loci, which, while not tagged by the SNP, are found to affect the same genetic factor as the common variant; thus GWAS loci that reveal common variants may also reveal rare variants.
What of rare variants that occur at different loci than identified by GWAS? How can we find them? The alternative to map-based genetics is to study candidate genes selected from prevailing knowledge in biology. However, this approach is challenged by the fact that association studies show that the majority of GWAS signals fall outside any genes that were considered as candidates and moreover, implicate genes that were never before thought to be involved [15] . The study by Nejentsev et al.'s illustrates how apart from a GWAS-implicated locus, nine other non-GWAS (but rationally chosen) candidates failed to show association to rare variants. Clearly, we need to understand more about the systems biology of pathways before we are capable of predicting candidates effectively. Fortunately, we may not need to predict candidates because advances in technology mean that we can now contemplate sequencing complete functional subsets of the genome. This is based on the thinking that any perturbation of biological function by a genetic variant could increase risk of disease. Of course, targeted sequencing of all known exons, the exome is the obvious first stop. However, of the regions mapped by GWAS, a significant portion tag SNPs outside exons and are presumably regulatory variants, which have long been hypothesized as playing the major part in phenotypic variation [59] . These regulatory regions include promoters which are close to exons but some GWAS associated SNPs have shown they can be hundreds of kilobases away [15] which suggest they are enhancers. For example, a strong association to body mass index maps 188 kb downstream of MC4R (melanocortin-4 receptor), a gene which is linked to childhood obesity [60] . One study found more than 55 000 enhancers and suggested there are 10 5 -10 6 in the human genome in total [61] . Therefore it appears that the ENCODE (ENCyclopedia Of DNA Elements; http://www.genome.gov/10005107) set of functional elements would be at least as valid for targeted sequencing as exons [62] .
However, due to their random or 'shotgun' nature next generation technologies are not set up for selecting specific parts of the genome for sequencing. Therefore, separate technology needs to be used for genome selection before entering into the sequencing pipeline. PCR is problematic where the length of a region is beyond the range of long-range PCR or the regions of interest are numerous. A number of methods for improving multiplexing of PCR [63, 64] and several alternatives to PCR are in development. One set of approaches have evolved from molecular inversion probes (MIP) and padlock probes [65, 66] ; notably 50 000 exons have been selected and sequenced using a MIP-based method [67] . The cost and effort of generating 50 000 or more oligonucleotides can be alleviated by using microarrays to generate solution mixtures of oligonucleotides.
Another set of approaches enrich specific sequences on the basis of affinity to a complementary probe. Affinity-based approaches may be capable of separating out haplotypes [68, 69] . Affinityenrichment (or 'pull-down') can be implemented on a microarray where probes targeting numerous short regions or tiling through a single long region can be provided [70] . The probes can be used in solution for affinity capture after they are cleaved from the array [71] . A solution based-selection approach, combined with mismatch repair detection (MRD) has been shown [72] to be capable of detecting rare variants at a frequency as low as 1 in 100,000, using Affymetrix resequencing by hybridization arrays [73] for read-out. There is potential for combining resequencing arrays with sequencing-bysynthesis so that enrichment and sequencing can be done on a single platform [74] . Generally, at this stage the degree of enrichment and evenness of coverage are issues that remain to be tackled satisfactorily by genome selection approaches.
Several of the next generation technologies have in-built multiplexing capability, for example different samples can be applied to separate channels. To ramp-up the multiplexing further, samples can be tagged by inserting sequence-based barcodes and then pooled together [75] . Alternatively, the identity of a sample can be encoded in their distribution over a number of partially overlapping libraries [76, 77] . The multiplexing process can be integrated with selection as has been demonstrated [63] .
RESEQUENCING WHOLE GENOMES
There is a case for remaining open about which parts of the genome have functional consequences for a particular trait. For example, parts of the genome that were once considered as junk, may harbour yet to be discovered functional elements. Also, a fraction of the genome remains uncharted in regions that were refractory to Sanger sequencing; 341 gaps remained in the gold standard reference genome 250 of which were in euchromatic regions [78, 79] . Should we sequence everything and then look for association? Advances in technology have bolstered the case for sequencing whole genomes, a process which has begun, as described. Sequencing costs are rapidly decreasing and performance is improving; the sequencing performance from the first to the second AML patient by the same team improved from requiring 98 instrument runs to 16.5 and from 91% diploid coverage to 98% within the span of about a year [7] .
Sequencing-based association studies would allow us to move away from map-based genetics to direct variant genetics. The association study would start and end with the sequence. The whole genome sequence would have the potential to reveal, both disease associated genetic variants, rare or common, in a completely hypothesis-free manner. Rare variants found in particular genes or at particular loci where the frequency of each variant is too low to be picked out by itself by statistical association, may need to be binned together and compared in cases and controls [56] .
Where the aim of 1000 Genomes Project is to provide a resource that is not linked to phenotype, the Personal Genome Project (PGP) advocated by George Church [44] aims to provide open access to whole genome sequence of individuals whose personal phenotype information is also disclosed (http://www.personalgenomes.org/public/). The PGP is being conducted initially on ten consenting and well-informed volunteers but recruitment has already expanded to 13 000. The project aims to provide the research community a resource to conduct sequence, phenotype and health/lifestyle correlations themselves. Currently, the PGP website provides phenotypes ranging from height to photographs of the face and histories ranging from work ethic to diet.
Population sequencing will also need to be applied to more disease-targeted association studies that will be conducted by independent research teams having the necessary samples and expertise. It is also likely that whole genome resequencing will come to be applied in longitudinal cohort studies such as the UK Biobank [80] .
Tools are needed to link genome sequence to phenotype; Trait-o-matic, software for annotating sequence with links to phenotype was used to analyse a sequenced whole genome reported in the literature [5] and at time of writing data from four other sequenced genomes are on the web (http:// snp-dev2.freelogy.org/).
While orders of magnitude reduction in cost and increase in throughput are possible with next generation technology, the sheer number of individuals that need to be addressed in association studies means that whole genome sequencing is presently out of reach. It is expected that incremental improvements to existing next generation technology will lead to $10 000 per genome cost; although the ease of sequencing and the infrastructure required, including highly trained operation and analysis teams, needs to be considered. The logistics for handling the sequencing of large number of individual genomes will require highly efficient multiplex workflows to be developed.
For whole genome sequencing to become a practical proposition for association studies, a further generation of technologies may be needed. Strong candidates for such technology are methods that eliminate extensive sample preparation steps by looking directly at single molecules such as the Helicos technology used for sequencing the genome of a male of European descent [9] . That whole human genome sequencing was possible by looking directly at individual molecules rather than amplified molecules, supports a move away from traditional molecular biology which is heavy on labour and reagent cost to the new paradigm of single molecule biochemistry [81, 82] . While ensemble sequencingby-synthesis of clonal amplified molecules is subject to loss of synchrony or the phasing problem leading to substitution errors [83] , this is avoided in single molecule sequencing-by-synthesis by observing individual molecules extending asynchronously; the trade-off is an excess of deletion errors due to fluorophore dark states.
Single molecule methods that move away from the cyclic sequencing-by-synthesis concept which are theoretically promising but have yet to show full proof-of-principle include nanopore strand sequencing (detecting individual bases as a DNA strand passes through a narrow pore) and direct analysis of nucleotides by electron microscopy or scanning probe microscopy [84] [85] [86] [87] [88] . Another candidate technology, sequencing by hybridization of a complete set of short oligonucleotides, which has already been demonstrated on rolling circle amplification (RCA) generated tandem copies [89] , would gain great power if information on the location of a hybridization event along a single long genomic DNA molecule could be provided. A real-time sequencing approach, which amounts to watching the template-directed incorporation of nucleotides to a growing primer by a polymerase, is being developed [90] . In contrast to cyclic sequencing-bysynthesis technologies, real-time sequencing does not require exchange of reagents, which could mean simpler instrumentation, lower reagent costs and faster sequencing. Eid et al. (Pacific Biosciences; PacBio) have already reduced the concept to practice [90] . Although the polymerase that was used, Phi 29, has a processivity of $70 Kb, the potential for extremely long reads was tempered by specific types of read error; iteration of sequencing on each single molecule has the potential to produce a consensus read of good length and quality.
An alternative solution for the individual research team looking to ease the burden of large-scale sequencing is outsourcing to a sequencing factory. Currently, one company provide a 30Â sequencing service for $50 000 (http://www.illumina.com). Notably, another company (http://www.complete genomics.com) claim to have developed an industrial scale, in-house sequencing technology that is projected to be made available as a service this year at a remarkably low cost of $5000.
GENOME ASSEMBLY, STRUCTURALVARIATION AND HAPLOTYPES
Delivering the raw sequence reads is one thingassembling it is another [91, 92] . If sequencing reads could be the entire length of each chromosome, then we would capture genetic information in its native context. However, next generation sequencing reads currently range from just 35 to 450 bases which must then be assembled into contiguously overlapping segments (contigs) spanning as much of the genome as possible.
Initially, next generation sequence assembly has involved BLASTing [93] each sequence read against the reference human genome [1] . The computation time needed for this is not trivial however, and forms a major bottleneck in the sequencing pipeline. Alignment of portions of the sequence is complicated by the structure of the human genome, a substantial fraction of which comprises repetitive and transposable elements and >5% of which is duplicated [94] ; ambiguity arises over whether a sequence read maps to a first or duplicate copy of a genomic segment, one of which no longer being under selective pressure, may harbour an increase in variants. It should also be borne in mind that although the next generation technologies may obtain reads from regions previously refractory to sequencing, these reads are set aside when assembly is based on the reference genome, which is deficient in these sequences. A substantial fraction of reads from the genomes sequenced to date could not be mapped to the reference genome, which is not surprising as $25 Mb of euchromatic sequence is absent from the reference genome [79] .
There is therefore a case for switching from assembly by reference to the consensus genome to de novo genome assembly. Whether a reference genome exists or not, de novo assembly is the more computationally streamline option because it does not require repeated comparisons to a reference. A number of new de novo assembly algorithms based on de Bruijn graphs have been developed [95, 96] . Although the de novo methods have been used to stitch together contigs from reads that fall outside the reference genome [2, 97] it is currently difficult to use de novo assembly algorithms to assemble large genomes and to deal effectively with repeats.
While a diploid sequence is sufficient to study genetics, there are further benefits if the separate haploid or haplotype contributions from each chromosome or haplotypes can be resolved. Haplotypes add power to genetic studies and can be effective predictors of disease and tissue matching for transplantation [68, 98] . De novo haplotype assembly is particularly important for cancer genomes, which may diverge vastly from reference due to aneuploidy. A biopsy may provide cells with a whole range of chromosomal copy alterations and each of these chromosomes may carry its own spectrum of SVs.
How can we obtain a haplotype sequence? Haploid sequencing was done for one individual genome by sequencing BAC clones [5] but this is too laborious for routine implementation. When sequencing reads are reasonably long (800-1000 bases) as in Sanger sequencing, the likelihood of a particular haplotype can be computed by overlapping reads containing multiple heterozygotic sites, an analysis that was done on Venter's genome [2, 99] . The requisite read-lengths may also soon be within reach of clonal 454 reads and single molecule PacBio reads.
Long reads or a scaffold [46, 100] that places the reads or contigs in their long-range context can facilitate genome assembly and enable structural variation between individual genomes to be determined. Mate-pair libraries, which allow the physical linking of distal sequences from the same fragment, were used extensively in the human genome project. Several types of mate-paired or 'Paired-End Mapping (PEM)' approaches are being used in the context of next generation sequencing to help assemble genome sequence and to investigate SV [38, 101, 102] . When mapped to the reference genome if the reads from the pair are, with respect to each other, at longer or shorter intervals than expected or are in the opposite orientation than expected, then SV is indicated [103] . Haplotypes are also revealed if each read from the pair falls at heterozygotic sites [8, 10] ; using paired Sanger reads, haplotypes in segments of >200 kb were assembled for a substantial portion of Venter's genome [2, 99] .
However, the construction of mate-pair libraries can be expensive and labour-and time-consuming. It is difficult to comprehensively access long-range haplotypes. The full spectrum of SVs and chromosomal breakpoints in the genome, using next generation technology unless a range of short and long size inserts are used for pairing [104, 105] . Moreover, there are difficulties with detection of insertions, repetitive parts of the genome longer than insert size [10] and detection of SVs in complex, duplicated parts of the genome [51] . The length of insert is limited by the capacity of cloning vectors; to date, published mate-pair library next generation sequencing has not spanned greater than 3 kb, a size which would not cover all repeat elements nor longrange structural variants which are prevalent in the genome [105] . It is of concern that RD and PEM only overlap to a small extent [51] ; it is not clear therefore whether these methods access the full repertoire of SV.
An alternate approach based on HAPPY (HAPloid DNA samples using the PolYmerase chain reaction) mapping [106] has been suggested [107] , which is to prepare pools of DNA each comprising genomic DNA diluted to less than one genomic copy level, and then to infer genomic proximity of reads from their coincident prevalence in a given pool; each pool would be tagged so that it could be differentiated from others. Another means would be to supplement DNA sequencing with a personal genome map to which sequence reads could be pinned. This could be accomplished by some form of single molecule optical mapping; appropriate algorithms have been developed including those that would enable haplotype construction [108] but further refinement of experimental approaches as well as algorithms are needed [109] [110] [111] [112] .
As a third generation of sequencing technologies moves us towards single molecule detection, the opportunity exists for determining SV and haplotype directly on individual molecules of genomic DNA. It can be imagined that single very long reads may one day be possible using real-time or nanopore sequencing. Alternatively, methods are being developed that visualize sequence or sequence reads, along the length of single long DNA molecules that are stretched-out to display the sequence in a linear manner, using CCD-based optical or electron microscopy [84] .
CONCLUDING REMARKS
Genome-based medicine is beginning to find its way into diagnosis, disease staging and medical decisionmaking [113] . With the advent of ultra-low cost sequencing technology, it has been predicted that within 10 years sequencing of newborns will be routine [114] . Ethical issues abound but the 2008 signing by US Congress of the Genetic Information Non-discrimination Act (GINA) which prohibits misuse of genetic information in employment and health insurance is a step in the right direction (http://www.genome.gov/24519851).
A number of 'consumer genetics' companies already offer genotyping (http://www.23andme .com; http://www.navigenics.com; http://www .decodeme.com) and sequencing (http://www .knome.com) services direct to the public. However, based on our limited knowledge of genotype-phenotype relationship of complex traits in humans at this time, it is debatable whether these services offer value for money.
In their report on the sequencing of a Chinese individual, Wang et al. [10] were able to match a handful of complex traits with variant alleles that are risk factors for those traits; in the case of alleles implicated in tobacco addiction they noted that the individual is a heavy smoker. Whilst this serves to illustrate how personal sequencing can retrospectively be correlated to phenotype, for the majority of chronic diseases we are currently not in a position to make reliable predictions of health outcomes based on genome sequence [115] .
To make it worthwhile for an individual to have their genome sequenced for health prediction we need to apportion the heritable component of a number of common diseases more substantially. A large number of associations have been made for T2D but at this time knowledge of an individual's genotype at the 18 known T2D loci is no better at predicting the likelihood of disease than an individual's body mass index (BMI), sex, age and family history [116] .
Clearly, much more needs to be learnt about the specific variants that underlie common disease before sequencing en masse of non-symptomatic individuals can be seriously contemplated as a routine part of healthcare. Given the degrees of heritability attributed to various common diseases however, personal genomic sequencing and tools to calculate risk will no doubt become imperative when we have determined substantially more of the heritable component. Until then genomic sequencing in scientific pursuit of the variants that underlie the complex traits is nonetheless crucial.
At this point, apart from the 10% or so apparent weighting of common variants we do not know the extent of contribution of rare single nucleotide and structural variants. If rare variants are found to have a large effect for a given disease then they may account for a substantial proportion of the missing heritability for that disease [117] , however in the case of IFIH1 gene which carries protective rare variants for T1D, the variants that were discovered had a small to moderate effect [58] so many more variants are likely to be needed to explain the heritable component. There is a worry that more variants than are manageable may be involved [117] . Notwithstanding this concern, high-accuracy sequencing will still reveal the diversity of variations present in an individual but genetic risk assessment tools will need to be all the more sophisticated and we may require the underlying molecular mechanisms to be understood [118] .
It is also clear that at this time we do not know the extent of contribution of epigenetic effects [119] such as gene-gene (including gene-regulatory element interactions) and gene-environment interactions. Statistical methods have been developed to help unravel gene-gene interactions [120, 121] and will become more powerful with improved study breadth and design [122] . Gene-gene interactions will also be unravelled by functional studies, knowledge from which could be incorporated into new statistical analysis methods. New experimental methods to decipher long-range intra-chromatin interactions have recently emerged but may be difficult to apply at a genome-wide scale in populations [105] . Sequencing the human microbiome [123] and deciphering their gene products will facillitate a portion of the interactions of human genes with the 'environment' to be unravelled.
What are the mechanisms that translate environmental effects into phenotype changes? [124, 125] The environment and biological history from conception onwards can leave a detectable imprint on the genome. Chemical modifications at the DNA and the chromatin level, namely methylation on DNA and methylation/acetylation on histones can control the expression of parts of the genome. Currently, the epigenome which comprises methylation of specific cytosines in the genome, can be addressed by bisulphite sequencing and in the future emerging technologies may make it possible to obtain methylation status at same time as reading base identity [126] .
Once we are at a point where a large number of individuals have been sequenced whether by researcher-or consumer-led sequencing (or a combination of the two) and their genotype, phenotype, environmental exposures and medical history are available then the resulting population scale data would give genetic epidemiological investigation [127, 128] substantial power. When sequencing is on the scale of populations, we will enter a virtuous cycle, where the more we sequence the more we learn. The close integration of epidemiology with genetics will place genetic risk factors in their broader public health context and help to avoid genetic determinism.
By helping us gain a better understanding of pathways involved in disease [129] , the sequencing of individuals in affluent countries will, in the longer run, also benefit those whose genome is not sequenced. On the flip side, surveying different ethnic populations, particularly in relation to disease, will also yield biological insights that are of medical benefit to all populations.
In the future, human genomic sequencing and transcriptome sequencing [130] (not discussed here) are likely to play a role throughout life, whether for sequencing of nucleic acids from circulating cells for early detection of cancer or for monitoring the diversity and load of microorganisms within the human microbiome [123] . The first whole genome sequencing of individuals with disease phenotype has shown that comparison between normal and tumour cells, allows discrimination of somatic from inherited mutations; variants recurrent in cancer genomes may reveal driver mutations for tumour pathogenesis, providing possible leads for drug discovery and therapy [6, 7] . It can be imagined that in the future, personalized medicine may be based not only on the genome and epigenome that we are born with but also the one we end up with in different parts of our body, through somatic mutations and epigenetic modifications. Sequencing of complete individual genomes is a reality. An individual genome has been sequenced using single molecule technology. The human genome is currently not sufficiently annotated with links to phenotype for personal sequencing to have a significant impact on personalized health management. Selective, deep and multiplex sequencing methods are important for a number of applications including disease diagnostics. Sequencing based association studies are likely to be informative but cost reduction and multiplex work-flows are needed. Genome sequencing can lead to identification of somatic mutations that are putatively involved in disease. An individual's genome sequence must be considered in the context of epigenetic/environmental factors and within a socioethical framework.
